## CME Credits:

*Credits for Specialists:* This event is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification program of the Royal College of Physicians and Surgeons of Canada, and approved by Queen’s University.

## Learning Objectives:

- To identify and address, through clinical and translational research, the disease burden associated with pancreatic malignancies in Canada.
- To identify clinical trial research opportunities in pancreatic malignancies within the Canadian Cancer Trials Group.
- To integrate current knowledge regarding therapeutics and tumour biology in trial concept development and conduct as these relate to pancreatic malignancies.
- To integrate and apply new clinical trial methodologies in pancreatic malignancies in the Canadian Cancer Trials Group research agenda.
- To provide a learning and mentoring environment supportive to new investigators.

## Schedule:

<table>
<thead>
<tr>
<th>Time</th>
<th>Activity</th>
<th>Presenter(s)</th>
</tr>
</thead>
</table>
| 10:45 am | Welcome | Dr. D. Renouf  
Dr. A. Wei |
| 10:50 am | PA.6 (ACCORD 24): Randomized Multicenter Phase III Comparison of Adjuvant Chemotherapy with Gemcitabine versus a Combination of 5-Fluorouracil, Leucovorin, Irinotecan And Oxaliplatin (mFOLFIRINOX) in Patients with Resected Pancreatic Adenocarcinoma | Dr. J. Biagi  
Dr. A. Wei |
| 10:55 am | Alliance A021806: Perioperative Versus Adjuvant Chemotherapy for Resectable Pancreatic Cancer | Dr. D. Renouf  
Dr. A. Wei |
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Presenter(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:05 am</td>
<td>PA.7: A Randomized Phase II Trial of Gemcitabine and Nab-Paclitaxel vs. Gemcitabine, Nab-Paclitaxel, Durvalumab and Tremelimumab as 1st Line Therapy in Metastatic Pancreatic Adenocarcinoma</td>
<td>Dr. D. Renouf</td>
</tr>
</tbody>
</table>
| 11:15 am | Concept: FLIP-PANC: 5-Fluorouracil, nanoliposomal Irinotecan, and Palbociclib in Patients with advanced pancreatic ductal Adenocarcinoma and CDKN2A mutations | Dr. E. Tsang          
                          Dr. D. Renouf             |
| 11:25 am | COMPASS/PANGEN Update                                                                                     | Dr. D. Renouf         |
| 11:30 am | Intergroup Task Force Update                                                                             | Dr. D. Renouf         
                          Dr. A. Wei                |
| 11:40 am | Meeting Adjourned                                                                                          |                       |